| Sept. 13, 2011 |
|
Merck Statement on GARDASIL® |
| Sept. 13, 2011 |
|
Merck Provides Update on the IMPROVE-IT Trial |
| Jul. 1, 2011 |
|
Merck Statement on Voluntary Submission of Clinical Research Protocols for its Investigational and Approved Products |
| Oct. 28, 2010 |
|
Merck Statement on Investigation of PCV Presented at Advisory Committee on Immunization Practices Meeting |
| Oct. 14, 2010 |
|
Merck Statement on Remicade and Simponi Arbitration |
| Mar. 19, 2010 |
|
Merck Statement on the Safety of Highest Dose of Simvastatin |
| Mar. 16, 2010 |
|
WHO Extends Prequalification of Merck's ROTATEQ® for Global Use |
| Mar. 11, 2010 |
|
Merck Provides Update on the IMPROVE-IT Trial |
| Mar. 10, 2010 |
|
Merck Responds to News Reports about FOSAMAX® (alendronate sodium) Tablets |
| Feb. 18, 2010 |
|
Merck and Novartis Statement in Response to the FDA’s February 18, 2010 Communication Regarding Long-Acting Beta2-Agonists, including FORADIL® AEROLIZER® (formoterol fumarate inhalation powder) |
| Jan. 07, 2010 |
|
Merck Statement on Clinicaltrials.gov Update Regarding the IMPROVE-IT Trial |
| Nov. 30, 2009 |
|
Merck Argues VIOXX® Case before U.S. Supreme Court |
| Nov. 23, 2009 |
|
Merck Statement on Article in The Archives of Internal Medicine Involving VIOXX® |
| Oct. 22, 2009 |
|
The Supreme Court of Canada Will Not Review the Saskatchewan Court of Appeal Judgment Overturning a Class Certification Order in VIOXX® Action
|
| Oct. 19, 2009 |
|
Merck Statement on U.S. Speaker Fees Company Achieves another Milestone in Its Ongoing Transparency Initiative |
| Sept. 25, 2009 |
|
Merck Statement About JANUVIA™ (sitagliptin) and JANUMET™ (sitagliptin/metformin) |
| Sept. 24, 2009 |
|
Merck Statement on HIV Vaccine Trial |
| Aug. 11, 2009 |
|
Statement on FOSAMAX® (alendronate sodium) Product Liability Trial in U.S. District Court |
| Jul. 29, 2009 |
|
Statement by Merck & Co., Inc., Regarding FOSAMAX® (alendronate sodium) and Rare Cases of Osteonecrosis of the Jaw |
| Jun. 20, 2009 |
|
Merck & Co., Inc. Statement on Medicare Part D Assistance |
| Jun. 12, 2009 |
|
Merck Statement in Response to the FDA's June 12, 2009 Communication with Updated Information on Leukotriene Inhibitors, Including SINGULAIR® (montelukast sodium) |
| |
|
|
Patient Product Information |
